Pipeline — registered trials by phase
Immune Response Following Seasonal Influenza Vaccination
— · Influenza · Completed · est. 2017-11-21
Study of the Safety and Immunogenicity of NasoVAX Extension
— · Influenza · Completed · est. 2019-02-18
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
— · Hepatitis B · Completed · est. 2017-10-13
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
— · Influenza A Subtype H5N1 Infection · Completed · est. 2009-09
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
— · Non-Alcoholic Fatty Liver Disease · Completed · est. 2022-10-31
NasoShield in Healthy Adults to Study Safety and Immunogenicity
— · Healthy Volunteers · Completed · est. 2021-03-15
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
— · Type 2 Diabetes · Completed · est. 2023-02-03
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
— · Healthy Volunteers · Completed · est. 2021-12-01
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
— · NASH - Nonalcoholic Steatohepatitis · Completed · est. 2022-05-15
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
— · Obesity, Nonalcoholic Steatohepatitis · Completed · est. 2021-10-29
NasoShield Study of Safety and Immunogenicity
— · Healthy Volunteers · Completed · est. 2019-05-13
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
— · Non-Alcoholic Fatty Liver Disease · Completed · est. 2022-08-17
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
— · Non-Alcoholic Steatohepatitis (NASH) · Completed · est. 2025-11-25
Efficacy and Safety of ALT-801 in the Treatment of Obesity
— · Obesity/Overweight · Completed · est. 2023-09-28
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
— · Alcohol Use Disorder (AUD) · Completed · est. 2026-07-30
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
— · Alcohol-associated Liver Disease · Active Not Recruiting · est. 2027-09-30
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
— · Influenza · Completed · est. 2018-03-07
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
— · Metabolic Dysfunction-Associated Steatohepatitis (MASH) · Recruiting · est. 2028-12
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Altimmune is lead sponsor; 18 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-29Current report (material event)
- 10-Q2026-08-12Quarterly report
- 8-K2026-08-12Current report (material event)
- 8-K2026-07-28Current report (material event)
- 8-K2026-06-16Current report (material event)
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- S-82026-05-13Employee stock plan
- 10-Q2026-05-13Quarterly report
- 8-K2026-05-13Current report (material event)
- SCHEDULE 13G2026-05-12SCHEDULE 13G
- SCHEDULE 13G2026-05-01SCHEDULE 13G
- SCHEDULE 13G2026-05-01SCHEDULE 13G
- SCHEDULE 13G2026-05-01SCHEDULE 13G
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 8-K2026-04-24Current report (material event)
- 424B52026-04-24Prospectus (offering)
- S-3MEF2026-04-22S-3MEF
- 424B52026-04-22Prospectus (offering)
- 8-K2026-04-16Current report (material event)
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- ARS2026-03-17Annual report to holders
- DEF 14A2026-03-17Proxy statement
- PRE 14A2026-03-06PRE 14A
- 10-K2026-03-06Annual report
- 8-K2026-03-05Current report (material event)
- S-82026-02-06Employee stock plan
- 8-K2026-02-03Current report (material event)
- SCHEDULE 13G/A2026-01-30SCHEDULE 13G/A
- 8-K2026-01-28Current report (material event)
- 424B52026-01-28Prospectus (offering)
- 8-K2025-12-19Current report (material event)
- EFFECT2025-12-05EFFECT
- CORRESP2025-12-03CORRESP
- 8-K2025-12-01Current report (material event)
- S-3/A2025-11-13S-3/A
- S-32025-11-06Shelf registration
- 8-K2025-11-06Current report (material event)
- 424B52025-11-06Prospectus (offering)
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-06Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.